Jointown(SH:600998) Zhi Tong Cai Jing·2025-10-16 11:10Core Viewpoint - The company Kyushu Tong (600998.SH) announced that its subsidiary Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd. received approval from the National Medical Products Administration for the marketing application of Glycopyrrolate, a quaternary ammonium anticholinergic drug [1] Group 1: Product Approval - The approval notification for Glycopyrrolate was issued on October 16, 2025 [1] - Glycopyrrolate is indicated for conditions such as gastric and duodenal ulcers, chronic gastritis, and for maintenance treatment in adults with chronic obstructive pulmonary disease (COPD) [1] Group 2: Drug Mechanism and Applications - Glycopyrrolate selectively acts on the gastrointestinal tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] - The drug specifically binds to and inhibits the M3 acetylcholine receptors in bronchial smooth muscle, leading to airway dilation [1]